Nephrology News
NODAT Risk Similar After Switching From CNIs to Everolimus
The incidence of NODAT was 33.8% among patients who switched to everolimus and 36.4% among those who stayed on calcineurin inhibitors.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/